Related Experiment Video

Updated: Aug 19, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Insulin-like growth factor-I and breast cancer therapy

Yasir H Ibrahim1, Douglas Yee

  • 1University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 11, 2005
PubMed

Insights

The insulin-like growth factor (IGF) system fuels breast cancer growth. Therapies targeting IGF signaling pathways show promise for treating breast cancer by inhibiting tumor development.

Area of Science:

  • Oncology and Endocrinology
  • Molecular Biology and Cancer Research

Background:

  • Hormonal and growth factor signaling pathways are crucial in breast cancer development.
  • The insulin-like growth factor (IGF) system is implicated in promoting breast cancer cell proliferation, metastasis, and survival.
  • Evidence from in vitro, animal, and epidemiological studies supports the role of the IGF system in breast cancer biology.

Purpose of the Study:

  • To discuss the relevance of the insulin-like growth factor (IGF) system in breast cancer.
  • To review pharmacologic interventions targeting the IGF system for breast cancer treatment.
  • To explore the potential clinical impact of anti-IGF therapies in managing breast cancer.

Main Methods:

  • Review of in vitro, animal, and epidemiological evidence on the IGF system in breast cancer.
  • Discussion of different strategies to target the IGF system, including ligand production, binding, and receptor activation.
  • Analysis of directed anti-IGF strategies and their potential clinical applications.

Main Results:

  • The IGF system plays a significant role in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer.
  • Pharmacologic interventions targeting the IGF system are under development to combat tumorigenesis.
  • Strategies include reducing IGF ligand production, blocking ligand-receptor interactions, or inhibiting receptor activation.

Conclusions:

  • Targeting the IGF system is a viable therapeutic strategy for breast cancer.
  • Directed anti-IGF therapies have the potential for significant clinical impact in breast cancer treatment.
  • Further research and development of these targeted therapies are warranted.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.